IUPAC: 2-(diphenylmethoxy)-N,N-dimethylethan-1-amine · C17H21NO · MW 255.36 g/mol · CAS 58-73-1 · ChEMBL657
Diphenhydramine (Benadryl). First-generation ethanolamine H1 antihistamine, approved 1946 — antihistamine, antiemetic, antitussive, and the sedative in nearly every OTC "PM" sleep aid (Nytol, ZzzQuil, Tylenol PM). Therapeutically benign; at the recreational / overdose doses (≥300–500 mg) it becomes an antimuscarinic deliriant and, higher still, a cardiac sodium-channel blocker — the pharmacology of a tricyclic-antidepressant overdose.
Diphenhydramine is a first-generation ethanolamine antihistamine. Its defining action is histamine H1 receptor inverse agonism (Ki ≈ 16 nM) — it does not merely block histamine, it stabilizes the inactive conformation of the receptor and suppresses its constitutive Gq activity. Because it is small, lipophilic (cLogP ≈ 3.3), and freely crosses the blood–brain barrier, central H1 blockade — not peripheral antihistamine effect — dominates the subjective profile: sedation.
The critical pharmacological fact is that diphenhydramine is promiscuous. Its affinities at muscarinic (M1 Ki ≈ 83 nM), cardiac potassium (hERG), and sodium (Nav1.5) targets sit only 5–2500× below its H1 affinity. At a 25–50 mg therapeutic dose the H1 occupancy carries the effect; as the dose climbs into the hundreds of milligrams, receptors that were pharmacologically silent light up in order of affinity — muscarinic first (delirium), then the cardiac channels (dysrhythmia). One molecule, three toxidromes, separated only by concentration.
Central H1 blockade in the tuberomammillary nucleus histaminergic projections shuts down the wake-promoting histamine tone to cortex and thalamus — the mechanism of drowsiness. This is also why tolerance to sedation develops within days.
Competitive antagonism at muscarinic ACh receptors (M1 Ki ≈ 83 nM) produces the peripheral anticholinergic effects (dry mouth, urinary retention, mydriasis, tachycardia) — and, centrally, the deliriant syndrome at high dose.
Like a local anesthetic or TCA, diphenhydramine blocks the cardiac fast sodium channel (IC50 ≈ 41 µM at rest). Block is use-dependent — worse at fast heart rates and depolarized tissue — so it emerges specifically in overdose: slowed phase-0 upstroke → QRS widening.
Diphenhydramine blocks the hERG (Kv11.1) potassium channel (IC50 ≈ 2.6–32 µM across assays), lengthening repolarization → QT prolongation and torsades-de-pointes risk that compounds the Nav conduction slowing in overdose.
Diphenhydramine is not a dopaminergic or serotonergic reinforcer — no DAT/SERT release at relevant concentrations. The high-dose experience is a dysphoric, confusional delirium, not euphoria. This is the pharmacology of an unpleasant drug, not a fun one.
Sustained muscarinic blockade (ACB scale score 3, the highest tier) is epidemiologically linked to cognitive decline and incident dementia with cumulative use — a real cost of habitual OTC "PM" sleep-aid reliance in older adults.
The doxepin-bound H1 crystal structure (PDB 3RZE, right) shows exactly why the ethanolamine antihistamines are so sedating and so promiscuous: a protonated tertiary amine anchors to Asp1073.32 by salt bridge deep in the seven-transmembrane bundle, while two lipophilic aromatic rings splay into a broad, shallow, weakly-specified hydrophobic pocket. That loose aromatic cradle is easy to satisfy — which is precisely why the same scaffold also fits the muscarinic and cardiac-channel pockets.
Diphenhydramine is well absorbed orally but subject to extensive first-pass metabolism, giving an oral bioavailability of only ~40–60%. It is highly lipophilic with a large volume of distribution, so it partitions heavily into tissue (including CNS) and clears slowly — an adult elimination half-life of 8–9 h that stretches to ~13.5 h in the elderly, prolonging next-day sedation and anticholinergic hangover.
Metabolism cascade: two successive N-demethylations (CYP2D6-dominant, with CYP1A2/2C9/2C19 support) strip the dimethylamino group, then the resulting amine is oxidatively deaminated to the inactive carboxylic acid, which is conjugated and renally excreted.
Diphenhydramine is itself a moderate CYP2D6 inhibitor, so it can raise plasma levels of co-ingested CYP2D6 substrates (metoprolol, venlafaxine, tricyclics, many antipsychotics) — clinically relevant because several of those substrates are also QT-prolonging or cardiotoxic. CYP2D6 poor metabolizers (~7–10% of Europeans) clear the parent drug more slowly, amplifying and prolonging exposure at any given dose.
At therapeutic doses diphenhydramine just makes you sleepy. The "high" that circulates in adolescent and drug-naïve populations requires massive doses (typically 300–700 mg, sometimes more), at which point central muscarinic blockade drives a true anticholinergic delirium — the same class of experience as datura, scopolamine, or belladonna. It is consistently described by people who have taken it as frightening and dysphoric, not euphoric. This is not moralizing; it is what the pharmacology produces.
Unlike serotonergic psychedelics (where users know the visuals are drug-induced), the deliriant produces hallucinations indistinguishable from reality — spiders, insects, phantom people, and the widely-reported recurring "hat man"/shadow figures that users converse with and only later realize were never there. Loss of insight is the defining, dangerous feature: people act on things that are not real.
Central anticholinergic syndrome: disorientation, agitation, incoherent speech, frank confusion, and dense anterograde amnesia for the episode. The mood is overwhelmingly negative — dread, panic, discomfort — with none of the reward pharmacology that reinforces stimulant or opioid use. Redose-driven compulsion is rare precisely because the experience is miserable.
The classic mnemonic: blind as a bat (mydriasis, blurred vision), dry as a bone (no sweat/saliva), red as a beet (cutaneous vasodilation), hot as a hare (anhidrotic hyperthermia), mad as a hatter (delirium), plus urinary retention and tachycardia. Hyperthermia and the delirium-driven behavior are genuine acute dangers, independent of the cardiac effects.
Diphenhydramine scores the maximum 3 on the Anticholinergic Cognitive Burden (ACB) scale. Prospective cohort data (Gray et al., JAMA Intern Med 2015) link higher cumulative anticholinergic exposure to increased incident dementia — a reason first-generation antihistamines are on the Beers list of drugs to avoid in older adults, and a real cost of using OTC "PM" formulations as a nightly sleep aid.
Legitimate clinical uses remain broad and valuable: allergic reactions and anaphylaxis (adjunct), acute dystonia, antiemesis/motion sickness, antitussive, and short-term sedation. The problem is never the 25 mg tablet — it is the deliberate ingestion of ten or twenty of them.
Evidence-based, non-moralistic. Diphenhydramine overdose is dangerous in a specific, mechanistic way that is easy to underestimate because the drug is sold over the counter.
Binding free energy is ΔG = ΔH − TΔS, and diphenhydramine is a case study in the entropy term. The molecule carries a flexible ethanolamine tether (6 rotatable bonds) linking a protonated dimethylamino head to a benzhydryl (diphenylmethyl) tail. In free solution that chain samples a broad conformational ensemble — high Shannon entropy over its torsional microstates. On binding H1, the amine is pinned to Asp1073.32 by a salt bridge and the two rings are wedged into hydrophobic subpockets; the torsional ensemble collapses to a near-single conformer. That collapse is a real −TΔSconf penalty that the enthalpic salt bridge and aromatic/van-der-Waals contacts must pay for.
The doxepin·H1 structure (3RZE) shows the pocket that levies this cost is broad and weakly specified — a deep anionic anchor plus a shallow, forgiving aromatic cradle. From a FlexAID∆S standpoint this is exactly the geometry that produces polypharmacology: a pocket that does not demand a precise aromatic register imposes only a modest, similar entropic tax across a whole family of aminergic sites (M1–5, hERG, Nav1.5). The same rotatable-bond freeze that costs ~a few kcal/mol at H1 is paid nearly as cheaply at muscarinic and cardiac-channel pockets — so a single scaffold binds all of them with only a 5–2500× spread in Ki. Selectivity is, in entropic terms, the ability of one pocket to punish the ligand's flexibility more than its neighbors do; diphenhydramine's targets punish it about equally, which is why its therapeutic window and its toxidrome window are set by dose rather than by binding specificity.
The Nav1.5 story adds a second-order twist: block there is use-dependent, meaning the ligand preferentially engages the open/inactivated channel conformation. Modeling that interaction requires accounting for the conformational entropy of the channel, not just the ligand — the affinity that matters in an overdose is not the resting-state IC50 (~41 µM) but the far tighter apparent affinity for the rapidly-cycling channel of a tachycardic, seizing patient. Entropy is not a footnote to this drug's danger; it is the axis along which one benign tablet becomes a tricyclic-style poisoning.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
H1
Histamine H1 receptor (HRH1)
|
Ki = 16 nM
range 15–20 nM
|
Inverse agonist | |
|
M1
Muscarinic ACh receptor M1 (CHRM1)
|
Ki = 83 nM
|
Antagonist | |
|
hERG
Kv11.1 · KCNH2 (IKr)
|
IC50 ≈ 2.6–32 µM
|
Blocker | |
|
Nav1.5
Cardiac sodium channel · SCN5A
|
IC50 ≈ 41 µM
rest state · use-dependent
|
Blocker |